In this study, we evaluated the potential synergistic effects of AR inhibition and targeted alpha therapy by studying the antitumor effects of darolutamide in combination with radium-223 in LNCaP prostate cancer cells in vitro, as well as in an intratibial LNCaP xenograft model mimicking prostate cancer metastasized to bone. Here, AR is linked to prostate carcinoma.